Abstract
Background
After an acute deep venous thrombosis (DVT) of the lower limb, 20% to 63% of patients develop post-thrombotic syndrome (PTS). In this review, we address the efficacy of compression therapy in the treatment of acute DVT of the lower limb, and for the prevention of PTS.
Methods
12 randomized controlled trials (RCTs) and one meta-analysis, with a total of 3751 patients, were identified in a structured literature search.
Results
Two RCTs showed that adding compression therapy to drug treatment in the first 9 days of the acute phase of lower limb DVT led to more rapid pain relief (p<0.050) and less swelling (remaining difference in circumference, 1 cm versus 3 cm, p<0.050). As for the prevention of PTS, four RCTs showed a short-term benefit or no benefit of compression therapy. In three further RCTs, medical compression stockings (MCS) brought about a 16% to 27% absolute reduction of the frequency and severity of PTS (47% vs. 20 %, p<0.001; 40% vs. 21% (95% confidence intervals [29.9; 50.1] and [12.7; 29.5], respectively; and 58% vs. 42%, relative risk [RR] 0.73 [0,55; 0.96]). The benefit of MCS was also confirmed in a recent meta-analysis (RR 0.66 [0.44; 0.99], I2 = 88%). Thigh-length MCS were not superior to knee-length MCS for the prevention of PTS (33% vs. 36%, hazard ratio [HR] 0.93 [0.62; 1.41]). Individual, symptom-oriented tailoring of the duration of treatment was not inferior to a fixed treatment duration of 24 months (29% vs. 28%; odds ratio [OR] 1.06 [0.78;1.44]).
Conclusion
Compression therapy relieves symptoms in acute DVT and lessens the frequency and severity of PTS. It is therefore recommended as standard treatment.
CME plus+
This article has been certified by the North Rhine Academy for Continuing Medical Education. Participation in the CME certification program is possible only over the internet at http://daebl.de/RY95. The deadline for submissions is 21 March 2025.
Participation is possible at cme.aerztebatt.de
Acute deep venous thrombosis (DVT) of the lower limb is characterized by an obstruction of the deep veins and muscular veins by thrombi, carrying the risk of potentially life-threatening embolization into the pulmonary circulation. Following proximal lower limb DVT, that is to say, affecting at least the popliteal vein, 20–63% of patients develop post-thrombotic syndrome (PTS), which, depending on the diagnostic criteria, causes a feeling of heaviness, a tendency to swelling, and pain. Patients may suffer different stages of chronic venous insufficiency (CVI) and even trophic disorders and ulceration. The Villalta score is used to establish the diagnosis and assess the severity of PTS (Table 1); this grades symptoms and clinical signs but does not record venous claudication (1, 2, 3, 4).
Table 1. Villalta score* for the diagnosis and clinical assessment ofthe severity of post-thrombotic syndrome (from 18, 28).
| Symptom intensity and findings | ||||
| Severity | Absent | Mild | Moderate | Severe |
| Symptoms | ||||
| Pain | 0 | 1 | 2 | 3 |
| Cramps | 0 | 1 | 2 | 3 |
| Feeling of heaviness | 0 | 1 | 2 | 3 |
| Paresthesia | 0 | 1 | 2 | 3 |
| Itch | 0 | 1 | 2 | 3 |
| Clinical findings | ||||
| Pretibial edema | 0 | 1 | 2 | 3 |
| Skin induration | 0 | 1 | 2 | 3 |
| Hyperpigmentation | 0 | 1 | 2 | 3 |
| Redness | 0 | 1 | 2 | 3 |
| Phlebectasia | 0 | 1 | 2 | 3 |
| Calf compression pain | 0 | 1 | 2 | 3 |
| Venous ulcer | No | Yes | ||
*A Villalta score ≥ 5 points or the presence of a venous ulcer defines a PTS.
The score distinguishes between mild PTS (5–9 points), moderate PTS (10–14 points), and severe PTS (≥ 15 points or the presence of a venous ulcer).
PTS, post-thrombotic syndrome
The cause of the symptoms is venous stasis, which results either from delayed venous outflow due to persistent thrombi (occlusive type) or from post-thrombotic damage to venous valves and venous wall scarring (reflux type). Compression therapy counteracts venous hypertension and achieves a reduction in capillary leakage and edema. It improves the microcirculation of the skin and, by means of muscle compression, helps to reduce the diameter of the deep veins in the lower leg and support venous valve function (5).
Compression therapy can be carried out with phlebological compression bandages (PCB), medical compression stockings (MCS), or inelastic, medical adaptive compression systems and is simple and cost-effective to use. Moreover, in randomized controlled trials (RCTs), these treatment methods were able to reduce the risk of developing PTS by up to 50%. Therefore, guidelines recommended the wearing of MCS—with, however, a low level of recommendation in some cases (6, 7, 8). In 2014, the results of the SOX study (1) called compression therapy into question. Since then, there has been controversy regarding the benefits of compression therapy (9).
In consideration of the question of whether compression therapy improves symptoms in patients with acute lower limb DVT and reduces the risk of PTS, this review summarizes the currently available scientific data by means of a structured literature search and formulates recommendations for clinical routine on the basis of the current evidence.
Methods
For the review, the databases Medline, Embase, Web of Science, Cochrane Library, and the Regensburg Union Catalogue were searched by an independent person for the search terms: “compression treatment,” “compression stockings,” “compression hoisery,” “compression bandages,” “compression wraps,” AND “prevention of post-thrombotic syndrome.” The search was carried out for the period from 01.01.1990 and yielded 4384 hits (as of 24.08.2023). All hits were evaluated by two independent investigators with regard to study design and relevance according to pre-defined inclusion and exclusion criteria and using a quality standard checklist (power ≥ 80%, randomization, blinding, description of study dropouts, complete diagnostic work-up of the population, endpoint) (Figure 1) (10). From the remaining 132 publications, the 12 available RCTs and one meta-analysis including a total of 3751 patients and a follow-up period of 1–8 years were included in the review (Figure 2). All studies and recommendations were evaluated with regard to bias and evidence in accordance with the guidelines of the German Association of Scientific Medical Societies (Arbeitsgemeinschaft der Wissenschaftlichen Medizinische Fachgesellschaften e. V., AWMF) as well as using the levels of evidence as defined by the Oxford Centre for Evidence-Based Medicine (CEBM) (11) (12).
Figure 1.
Bar diagram showing the quality of the included randomized controlled interventional trials (n = 12)
RCT, randomized controlled trial
Figure 2.
Flow diagram of the literature search for the systematic review article (as of 24.08.2023)
APC, apparatus-based pneumatic compression; CVI, chronic venous insufficiency;
IPC, intermittent pneumatic compression; MCS, medical compression stockings;
PCB, phlebological compression bandage; RCT, randomized controlled trial;
DVT, deep venous thrombosis of the lower limb
Results and discussion of the evidence
Table 2 provides a summary of the RCTs included. Indications and questions regarding compression therapy are considered separately below.
Table 2. Summary of the 12 RCTs included.
| Publication | n | Intervention/control | Results in intervention vs. control group | Comments |
| Partsch & Blättler 2000 (13) | 45 (15/15/15) | Inelastic PCB vs. MCSvs. bed rest | Reduction in pain level (p < 0.050) andleg swelling (p < 0.010) after only day 2 vs. day 9 | More frequent progressionof thrombi in the femoral vein in the control group |
| Roumen-Klappe et al. 2009 (14) | 69 (34/35) | Inelastic PCB, later MCSvs. no compression | Reduction in leg swelling (remaining difference in circumference compared to healthy leg) 1 cm vs. 3 cm (p < 0.050) on day 7 | |
| Brandjes et al. 1997 (15) | 194 (96/98) | MCS vs. no compressionfor 24 months | PTS incidence of 20% vs. 47% (p < 0.001), severe pts 11% vs. 23% (p < 0.001) | |
| Prandoni et al. 2004 (16) | 180 (90/90) | MCS vs. no compressionfor 24 months | PTS incidence of 21% [12.7; 29.5] vs. 40% [29.9; 50.1] at 6 months, 24.5% [15.6; 33.4] vs. 49.1% [38.7; 59.4]at 24 months; HR 0.49 [0.29; 0.84] | |
| Aschwanden et al. 2008 (17) | 169 (84/85) | MCS vs. no compression | PTS incidence of 13.1% vs. 20.0%, RR 65% (OR 0.35 [0.17; 0.73]) at 3 months; RR 54% (OR 0.46 [0.23; 0.90]) at 12 months | Non-compliance more commonin men (OR 4.1 [1.0; 16.0]) |
| Jayaraj & Meissner 2015 (18) | 69 (36/33) | MCS vs. no compression | PTS incidence of 10% vs. 32% at 1 month, 20% vs. 40% at 3 months, 30% vs. 42%at 24 months | Loss to follow-up of over 50%,Venous Clinical Severity Score used |
| Kahn et al. 2014 (1) | 803 (409/394) | MCS vs. placebo stockings | Cumulative incidence of PTS withoutsignificant difference (HR 1.13, [0.73; 1.76]), high PTS rate of 52% in both groups | Delayed application, no instructions or treatment monitoring, compliance of only 55% |
| Yang et al. 2022 (20) | 232 (113/119) | MCS vs. no compressionfor 24 months | PTS incidence of 42.0% vs. 57.8%(RR 0.726 [0.547; 0.964]) | Iliofemoral thrombosis risk factor for PTS (RR 2.25 [1.14; 4.47]), high compliance for MCSprotective (RR 0.52 [0.28; 0.96]) |
| Prandoni et al. 2012 (24) | 267 (135/132) | Thigh-length MCS vs.knee-length MCS for 24 months | PTS 32.6% vs. 35.6% (HR 0.93 [0.62; 1.41]); severe PTS in three patients per group Discomfort, 41 % vs. 27 % (p = 0,02) | |
| Galanaud et al. 2022 (25) | 341 (169/159) | 25 mm Hg MCS vs.35 mm Hg MCS | PTS 31% vs. 33% (absolute difference−5.9% [14.7; 2.9], p = 0.0003 for non- inferiority | |
| Mol et al. 2016 (29) | 518 (256/262) | MCS for 12 months vs. 24 months | PTS incidence of 19.9% [16%; 24%] vs.13% [9.9%; 17%], NNT 14 | |
| Ten Cate-Hoek et al. 2018 (30) | 864 (432/424) | MCS for individualizedduration vs. 24 months | PTS incidence of 29% vs. 28% (OR 1.06 [0.78; 1.44]) |
HR, hazard ratio; MCS, medical compression stockings; OR, odds ratio; NNT, number needed to treat; PCB, phlebological compression bandage; PTS, post-thrombotic syndrome; [95% confidence interval]; RCT, randomized controlled trial;RR, relative risk reduction; vs, versus
Compression treatment in the acute phase of deep venous thrombosis of the lower limb
Partsch and Blättler first published a study in 2000 on the effect of treatment with thigh-length compression and mobilization on pain and leg swelling in acute proximal lower limb DVT compared to bed rest without compression. Each group of 15 patients was randomly assigned either to one of two intervention groups or to the control group. One intervention group received inelastic PCB in the form of a zinc paste bandage according to Fischer, while the other was treated with MCS in compression class (CCL) 2. Pain level and leg circumference both showed a significant reduction in the two intervention groups after 2 days, but not until after 9 days in the control group (pain: p < 0.050, swelling: p < 0.010) (13).
In the RCT conducted by Roumen-Klappe et al. in 2009, 34 lower limb DVT patients received a knee- or thigh-length PCB, depending on thrombus localization, as well as MCS once swelling had abated. The 35 lower limb DVT patients in the control group, on the other hand, were treated without compression therapy. After 7 days, the clinical symptoms of patients in the intervention group had significantly improved, including a reduction in leg swelling compared to the control group (a remaining 1-cm versus 3-cm difference in circumference compared to the healthy leg; p < 0.050) (14).
Evaluation
Despite the small number of subjects, there are significant differences between the groups with and those without compression therapy in the acute phase of symptomatic lower limb DVT. A PCB effectively reduces pain and leg swelling and can be easily adjusted to the diminishing leg circumference in the further course. For practical reasons, PCB with short-stretch bandages is generally used, despite the fact that zinc paste bandages were used in the original literature. The primary use of MCS in acute lower limb DVT was investigated in only one of the studies analyzed, but also shows positive effects. However, in the case of relevant leg swelling, the MCS should not be fitted until after decongestion using a PCB.
Recommendation: In acute symptomatic lower limb DVT, compression therapy shall be initiated immediately following diagnosis, since this leads to a faster reduction in pain and swelling.
Compression treatment for the prevention of post-thrombotic syndrome
Once pain and leg swelling have subsided, the question arises as to whether continued compression therapy can prevent PTS. The occurrence of PTS following first-episode acute proximal lower limb DVT was investigated by Brandjes et al. in 1997 and by Prandoni et al. in 2004. In both studies, the 194 and 180 patients, respectively, were randomized following acute management to receive either 2 years of knee-length MCS or no compression. The primary endpoint was the cumulative incidence of PTS, which was determined using the Villalta score over a period of up to 5 years (15, 16). Significant differences were seen in the incidence of PTS, namely, 20% and 25%, respectively, in the intervention groups versus 47% and 49%, respectively, in the control groups. It was found that MCS reduced the risk of developing PTS by 51% (HR 0.49 [0.29; 0.84]).
In their 2008 study on 169 patients, Aschwanden et al. reported that after proximal lower limb DVT, 13% of study participants with knee-length MCS developed trophic disorders in the affected leg (stage C4–C6 in the CEAP classification), compared to 20% in the control group. The authors were able to show that the relative risk reduction of 65% in the 3-month follow-up period declined to 54% over the course of 1 year, after which no more differences could be seen (17).
In 2015, Jayaraj and Meissner found positive effects (lower point score in the Villalta and Venous Clinicial Severity scores) at 1 and 3 months for compression therapy with knee-length MCS compared to no compression in, admittedly, only 69 included patients. However, these positive effects could not be demonstrated at 6 and 12 months. Having said that, the dropout rate was over 50% (18).
In 2014, Kahn et al. published the results of the SOX study. A total of 803 patients with acute proximal lower limb DVT received knee-length MCS or placebo stockings with less than 5 mm Hg pressure. The stockings were first used on average 2 weeks following diagnosis and without instructions, since both types (MCS and placebo) were sent by post. Compliance was deemed to be good if the MCS were worn on at least 3 days a week. This went down to 55.6% during the 24-month follow-up period (1). No group difference with regard to PTS incidence could be seen, neither when using the Ginsberg criteria (19) nor when determining the Villalta score.
Yang et al. (Epub) published a monocentric RCT in 2021 on compression therapy in acute proximal lower limb DVT (20). A total of 113 patients received knee-length MCS, while the 119 patients in the control group did not. The incidence of PTS based on the Villalta score at 24 months was 42% with MCS versus 58% in the control group (RR 0.73 [0.55; 0.96]). Iliofemoral thrombosis was a risk factor for PTS compared to femoropopliteal thrombosis. On the other hand, high compliance for MCS had a protective effect.
Evaluation
Three of the cited studies showed a significant reduction in absolute PTS risk of 16–27% at 2 years with compression therapy. Two studies were able to demonstrate positive effects only in the short term, whereas the SOX study found no benefit for compression therapy. However, the latter study cannot be extrapolated to medical practice in Germany since the MCS therapy was not initiated until after a 2-week delay, despite the fact that early compression is crucial for treatment success and symptom resolution (13, 14). The study showed a very high PTS incidence of 52% in both groups (based on the Villalta score), which seems to be most likely explained by low self-reported adherence of participants, a lack of objectively assessed treatment adherence, the severity of PTS, as well as the fact that accuracy of fit of the stockings was not verified. Since it is questionable whether compression therapy can be properly used without instruction and monitoring, the study ultimately does not enable any robust conclusions to be drawn regarding the effectiveness of compression on the prevention of PTS (21).
The meta-analysis published in 2023 by Meng et al. (RR 0.66 [0.44; 0,99]; I2 = 88%) (22)) as well as a 2017 Cochrane review conducted by Appelen et al. (RR 0.62 [0.38; 1.01]) (23) come to the same conclusions as the authors of the present article and confirm the efficacy of knee-length compression therapy in PTS prevention. It should be noted that the heterogeneity of the two meta-analyses is caused only by the negative findings of the SOX study with completely contrasting results in comparison. If one had excluded this study, the relative risk reduction in the Cochrane review would have been 50% ([0.38; 0.66]; p < 0.00001) (23). Therefore, PCB or MCS correctly applied under supervision as well as targeted medical patient information regarding the reason for and duration of the treatment remain the cornerstones of PTS prevention.
Recommendation: Patients with acute symptomatic lower limb DVT shall receive custom-fitted MCS, since it has been shown that these reduce the risk of developing PTS by up to 50%.
Length and pressure of compression stockings for the prevention of PTS
For compliance reasons, the question often arises as to whether knee-length MCS are sufficient and which class of compression should be prescribed. In 2012, Prandoni et al. compared the use of thigh-length MCS with knee-length MCS for 2 years in 267 patients with first-episode lower limb DVT with regard to cumulative incidence of PTS over 3 years, based on Villalta score. Compliance for thigh-length MCS was 71% versus 83% for knee-length MCS. PTS developed in 33% of patients with thigh-length and in 36% of patients with knee-length MCS (HR 0.93 [0.62; 1.41]). Stocking-related discomfort occurred more frequently in patients with thigh-length MCS (41%) compared to knee-length MCS (27%) (p = 0.02) (24).
The CELEST trial, conducted by Galanaud et al. and published in 2022, investigated 341 patients and found that thigh-length MCS with an ankle pressure of 25 mm Hg are not inferior to MCS with an ankle pressure of 35 mm Hg in PTS prevention. PTS developed in 29% of the 25-mm-Hg group and in 35% of the 35-mm-Hg group (25).
Evaluation
The only RCT investigating different stocking lengths was unable to demonstrate any statistically significant benefit for thigh-length compared to knee-length MCS in the prevention of PTS. The positive trend found in favor of thigh-length stockings would only have become significant once approximately 8000 patients had been included (23). Therefore, stocking length should be selected according to the symptoms of congestion. Due to the more rapid resolution of symptoms (13, 14), the AWMF S2k guideline on venous thromboembolism that was updated in 2023 also recommends thigh-length MCS for patients with additional thigh swelling (21). This applies in particular in the case of pelvic vein thrombosis, which already increases the risk for the development of PTS (20).
MCS in CCL 2 with an ankle pressure of 23–32 mm Hg, which is sufficient for most patients, are those most commonly prescribed (25). In the case of patients with severe PTS, one can escalate to CCL 3 with an ankle pressure of 34–46 mm Hg or flat-knit MCS (15, 16, 20, 26, 27, 28).
Recommendation: Patients with acute symptomatic lower limb DVT shall receive compression therapy with knee-length MCS (A-D) in CCL 2, since these prevent the development of PTS equally well compared to thigh-length MCS. In the case of acute symptomatic lower limb DVT and (additional) thigh swelling, compression therapy with thigh-length MCS (A-G) should be performed at least initially, since these result in a more rapid resolution of clinical symptoms.
Duration of medical compression stocking use for the prevention of PTS
The OCTAVIA RCT conducted by Mol et al. in 2016 investigated 518 patients with proximal lower limb DVT to determine whether the use of knee-length MCS for only 12 months is non-inferior to 24-month therapy with regard to PTS development. PTS developed in 20% when MCS was discontinued after 12 months, compared to 13% after 24 months. Evidence of non-inferiority was narrowly missed; the number needed to treat to prevent the development of one case of PTS after a further 12 months of MCS therapy was 14 (29).
The IDEAL-DVT trial conducted by Ten Cate-Hoek et al. in 2018 included 864 patients without pre-existing CVI who had already received compression therapy for 6 months following acute lower limb DVT. Patients were randomized either to treatment with knee-length MCS to be individually shortened in the case of two consecutively determined Villalta Scores ≤ 4, or treatment was continued for the 24-month duration of the study. PTS occurred in 29% of patients with an individualized treatment duration and in 28% with the standard treatment duration (30). In their 2018 supplementary analysis of the IDEAL-DVT trial, Amin et al. demonstrated a positive effect for the individualized treatment duration on quality of life and cost savings (31).
Evaluation
In patients with acute symptomatic CVT, compression therapy with individualized treatment duration is not inferior to the standard treatment duration of 24 months in terms of the prevention of PTS, meaning that the former should be preferred (29, 30, 31). The decision-making process can include the following:
An attempt at discontinuation over a few days
Villalta score
The results of digital photoplethysmography or venous occlusion plethysmography
The results of venous duplex ultrasound with regard to deep venous insufficiency and residual thrombus burden (21).
The meta-analysis by Meng et al. in 2023 (22) also found no benefit for compression therapy carried out over 24 months compared to a treatment duration tailored to patients’ symptoms, limited to 6–12 months (RR 1.18 [0.75; 1.85]; I2 = 76%).
Recommendation: In the case of acute symptomatic lower limb DVT, the indication to continue compression therapy beyond a duration of 6 months shall be reviewed on the basis of symptoms and clinical signs of chronic venous insufficiency. An individualized treatment duration should be favored over a fixed duration of 24 months.
Discussion and conclusions
The recommendation for compression therapy, which is to be initiated immediately upon diagnosis of lower limb DVT and carried out by professional staff, is based on the results of a number of RCTs and a recent meta-analysis. Despite overall small patient numbers, the lack of consistent blinding of study personnel, and the technical impracticability of blinding of patients, it can be concluded in summary that compression therapy has been shown to reduce not only swelling and pain in the acute phase of lower limb DVT but also the frequency and severity of PTS in the long term, as well as having a positive effect on the quality of life of those affected.
It is advisable to use PCB, preferably with short-stretch bandages (two-ply), as early on as possible in the acute phase if there is pronounced leg swelling and to fit MCS once leg swelling has subsided. If there is no or only slight venous congestion, knee-length MCS can also be used immediately. The respective recommendations can be found in the AWMF S2k guideline on the diagnosis and treatment of venous thrombosis and pulmonary embolism (21), which was updated in 2023, as well as in the guideline on medical compression therapy (8).
For the prevention of PTS, MCS are worn for an individually tailored duration, whereby treatment is guided by patients’ symptoms. Assuming there is no additional swelling of the thigh, the often better-tolerated knee-length MCS in CCL 2 are generally sufficient.
Questions on the article in issue 6/2024:
Compression Therapy in Acute Deep Venous Thrombosis of the Lower Limb and for the Prevention of Post-Thrombotic Syndrome
The submission deadline is 21 March 2025. Only one answer is possible per question.
Please select the answer that is most appropriate.
Question 1
Venous stasis in post-thrombotic syndrome can have various causes. Which term is used in the article for stasis that occurs due to damaged venous valves and vein wall scarring?
Reflux type
Occlusive type
Constrictive type
Occluded type
Constructive type
Question 2
Which of the following points is not cited in the text as a possible reason for the high incidence of PTS in the SOX study or the lack of robustness of the data?
2-Week delay in treatment initiation
Low self-reported adherence of participants
Lack of objectively assessed severity of PTS
Lack of verification of the accuracy of fit of the compression stockings
Use of the wrong score to assess the severity of PTS
Question 3
Which MCS ankle pressure is stated in the manuscript to be adequate for most patients when prescribed for the prevention of PTS (following lower limb DVT)?
3– 8 mm Hg
10–13 mm Hg
16–19 mm Hg
23–32 mm Hg
37–49 mm Hg
Question 4
Which statement on the duration of compression therapy following lower limb DVT is made in the article based on the available evidence for the prevention of PTS?
A treatment duration of 12 months should not be exceeded.
An individualized treatment duration should be favored over a fixed duration of 24 months.
A treatment duration of 12 months is significantly inferior to a treatment duration of 24 months.
A treatment duration of 6 months is adequate for all patients.
A treatment duration of between 6 and 12 weeks is generally adequate and should not be exceeded.
Question 5
Which instrument is used to diagnose and clinically assess the severity of post-thrombotic syndrome?
LEG score
PESI score
Villalta score
CHA2DS2-VASc score
HAS-BLED score
Question 6
What is reported in the article for the acute-phase treatment of lower limb DVT?
Compression treatment can significantly reduce clinical symptoms (such as pain and leg circumference) within only a few days.
Compression treatment may be initiated no earlier than 7 days following the diagnosis of lower limb DVT, once the initial leg swelling has subsided.
Compression treatment in the acute phase should be performed only with knee-length compression bandages, if at all.
Compression treatment can significantly reduce pain within only a few days, but has no effect on leg circumference.
Since compression therapy has no effect on acute-phase symptoms, only drug treatment is used.
Question 7
The studies by Brandjes et al. and Prandoni et al. (1997 and 2004, respectively) compared 2-year compression therapy with control therapy (without compression) following acute proximal lower limb DVT. Which outcome was reported regarding the cumulative incidence with and without compression for PTS in the follow-up period of up to 5 years?
Intervention: 20–25%; control: 21–26%
Intervention: 20–25%; control: 47–49%
Intervention: 35–40%; control: 18–23%
Intervention: 42–47%; control: 60–69%
Intervention: 13–17%; control: 51–58%
Question 8
Which of the following studies were not excluded from the literature search for the present review article?
Studies including pregnant women
Studies using pneumatic compression
Studies including patients aged under 18 years
Studies using additional interventional measures (thrombectomy, thrombolysis)
Studies using inelastic phlebological compression bandages
Question 9
Which recommendation on compression therapy for the purposes of PTS prevention in the updated 2023 AWMF S2k guideline on venous thromboembolism is mentioned in the article?
Knee-length MCS are generally recommended for men.
Knee-length MCS are generally recommended for patients with pelvic vein thrombosis.
Knee-length MCS are generally recommended for women.
Thigh-length MCS are generally recommended for patients with thigh swelling.
Thigh-length MCS are contraindicated in patients with thigh swelling.
Question 10
What does the abbreviation CCL stand for in the text?
Compression class
Clinical clothing
Compensation class
Compression clothing
Clinical class
Acknowledgments
Translated from the original German by Christine Rye.
Footnotes
Conflict of interest statement
BL was coordinator of the 2023 AWMF S2k guideline on the diagnosis and treatment of venous thrombosis (Leitlinie zu Diagnostik und Therapie der Venenthrombose). She is Managing Director of the DGA (German Society for Angiology – Society for Vascular Medicine) and a member of the GTH (German Society for Thrombosis and Hemostasis Research).
BL was a co-author of the 2023 AWMF S2k guideline on the diagnosis and treatment of venous thrombosis.
TN received honoraria for consultancy activities from Medi Bayreuth and speaker’s fees from Sigvaris. He received support for travel expenses from Medi Bayreuth and Sigvaris.
The remaining authors declare that no conflict of interests exists.
References
- 1.Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet. 2014;8:880–888. doi: 10.1016/S0140-6736(13)61902-9. [DOI] [PubMed] [Google Scholar]
- 2.Hach-Wunderle V, Bauersachs R, Gerlach HE, et al. Post-thrombotic syndrome 3 years after deep venous thrombosis in the thrombosis and pulmonary embolism in out-patients (TULIPA) PLUS Registry. J Vasc Surg Venous Lymphat Disord. 2013;1:5–12. doi: 10.1016/j.jvsv.2012.07.003. [DOI] [PubMed] [Google Scholar]
- 3.Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1–7. doi: 10.7326/0003-4819-125-1-199607010-00001. [DOI] [PubMed] [Google Scholar]
- 4.Mangwani J, Roberts V, Shannak O, Divall P, Srinivasan A, Dias J. Epidemiology and diagnosis of post-thrombotic syndrome: qualitative synthesis with a systematic review. J Clin Med. 2023;12 doi: 10.3390/jcm12185896. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Amin E, Joore MA, ten Cate-Hoek AJ. Compression to prevent PTS: a controversy? Phlebology. 2016;31(1 Suppl):41–47. doi: 10.1177/0268355516632986. [DOI] [PubMed] [Google Scholar]
- 6.Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S–e496S. doi: 10.1378/chest.11-2301. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Hach-Wunderle V, Abholz HH, Blank W, et al. S2k-Leitlinie Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Vasa. 2016;45(Suppl 90) [Google Scholar]
- 8.Rabe E, Földi E, Gerlach H, et al. S2k-Leitlinie Medizinische Kompressionstherapie der Extremitäten mit Medizinischem Kompressionsstrumpf (MKS), Phlebologischem Kompressionsverband (PKV) und Medizinischen adaptiven Kompressionssystemen (MAK) https://register.awmf.org/assets/guidelines/037-005l_S3k_Medizinische-Kompressionstherapie-MKS-PKV_2019-05.pdf (last accessed on 31 January 23) [Google Scholar]
- 9.Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149:315–352. doi: 10.1016/j.chest.2015.11.026. [DOI] [PubMed] [Google Scholar]
- 10.Khan KS, Kunz R, Kleijnen J, Antes G. Einleitung. In: Kunz R, editor. Sytematische Übersichten und Metaanalysen. Berlin, Heidelberg: Springer; 2004. pp. 1–7. [Google Scholar]
- 11.AWMF online - Portal der wissenschaftlichen Medizin. Auswahl und Kritische Bewertung der Evidenz. https://www.awmf.org/regelwerk/auswahl-und-kritische-bewertung-der-evidenz (last accessed on 22.10.2023) [Google Scholar]
- 12.Oxford Centre for Evidence-Based Medicine (CEBM) Levels of Evidence (March 2009) https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 (last accessed on 22.10.2023) [Google Scholar]
- 13.Partsch H, Blättler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg. 2000;32:861–869. doi: 10.1067/mva.2000.110352. [DOI] [PubMed] [Google Scholar]
- 14.Roumen-Klappe EM, den Heijer M, van Rossum J, et al. Multilayer compression bandaging in the acute phase of deep-vein thrombosis has no effect on the development of the post-thrombotic syndrome. J Thromb Thrombolysis. 2009;27:400–405. doi: 10.1007/s11239-008-0229-7. [DOI] [PubMed] [Google Scholar]
- 15.Brandjes DP, Büller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 1997;349:759–762. doi: 10.1016/S0140-6736(96)12215-7. [DOI] [PubMed] [Google Scholar]
- 16.Prandoni P, Lensing AW, Prins MH, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med. 2004;141:249–256. doi: 10.7326/0003-4819-141-4-200408170-00004. [DOI] [PubMed] [Google Scholar]
- 17.Aschwanden M, Jeanneret C, Koller MT, Thalhammer C, Bucher HC, Jaeger KA. Effect of prolonged treatment with compression stockings to prevent post-thrombotic sequelae: a randomized controlled trial. J Vasc Surg. 2008;47:1015–1021. doi: 10.1016/j.jvs.2008.01.008. [DOI] [PubMed] [Google Scholar]
- 18.Jayaraj A, Meissner M. Impact of graduated compression stockings on the prevention of post-thrombotic syndrome—results of a randomized controlled trial. Phlebology. 2015;30:541–548. doi: 10.1177/0268355514544781. [DOI] [PubMed] [Google Scholar]
- 19.Ginsberg JS, Hirsh J, Julian J, et al. Prevention and treatment of postphlebitic syndrome: results of a 3-part study. Arch Intern Med. 2001;161:2105–2109. doi: 10.1001/archinte.161.17.2105. [DOI] [PubMed] [Google Scholar]
- 20.Yang X, Zhang X, Yin M, Wang R, Lu X, Ye K. Elastic compression stockings to prevent post-thrombotic syndrome in proximal deep venous thrombosis patients without thrombus removal. J Vasc Surg Venous Lymphat Disord. 2022;10:293–299. doi: 10.1016/j.jvsv.2021.06.023. [DOI] [PubMed] [Google Scholar]
- 21.Linnemann B, Blank T, Doenst T, et al. Diagnostik und Therapie der tiefen Venenthrombose und Lungenembolie—AWMF-S2k-Leitlinie. https:/register.awmf.org/de/leitlinien/detail/065-002 (last accessed on 22.10.2023) 2023 Aug 25; [Google Scholar]
- 22.Meng J, Liu W, Wu Y, Xiao Y, Tang H, Gao S. Is it necessary to wear compression stockings and how long should they be worn for preventing post thrombotic syndrome? A meta-analysis of randomized controlled trials. Thromb Res. 2023;225:79–86. doi: 10.1016/j.thromres.2023.03.016. [DOI] [PubMed] [Google Scholar]
- 23.Appelen D, van Loo E, Prins MH, Neumann MHAM, Kolbach DN. Compression therapy for prevention of post-thrombotic syndrome. Cochrane Database System Rev. 2017;9 doi: 10.1002/14651858.CD004174.pub3. CD004174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Prandoni P, Noventa F, Quintavalla R, et al. Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. Blood. 2012;119:1561–1565. doi: 10.1182/blood-2011-11-391961. [DOI] [PubMed] [Google Scholar]
- 25.Galanaud JP, Genty-Vermorel C, Barrellier M, et al. 25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial. Lancet Haematol. 2022;9:e886–e896. doi: 10.1016/S2352-3026(22)00247-2. [DOI] [PubMed] [Google Scholar]
- 26.Blättler W, Zimmet SE. Compression therapy in venous disease. Phlebology. 2008;23:203–205. doi: 10.1258/phleb.2008.081004. [DOI] [PubMed] [Google Scholar]
- 27.Makedonov I, Kahn SR, Galanaud JP. Prevention and management of the post-thrombotic syndrome. J Clin Med. 2020;9 doi: 10.3390/jcm9040923. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kahn SR, Shapiro S, Wells Ph, et al. A multicenter randomized placebo controlled trial of compression stockings to prevent the post-thrombotic syndrome after proximal deep venous thrombosis: the S.O.X. Trial. Blood. 2012 [Google Scholar]
- 29.Mol GC, van de Ree MA, Klok F, et al. One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial. BMJ. 2016;353 doi: 10.1136/bmj.i2691. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Ten Cate-Hoek AJ, Amin EE, Bouman AC, et al. Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. Lancet Haematol. 2018;5:e25–e33. doi: 10.1016/S2352-3026(17)30227-2. [DOI] [PubMed] [Google Scholar]
- 31.Amin EE, Ten Cate-Hoek AJ, Bouman AC, et al. Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis. Lancet Haematol. 2018;5:e512–e519. doi: 10.1016/S2352-3026(18)30151-0. [DOI] [PubMed] [Google Scholar]